New variants of E6 and E7 oncogenes of human papillomavirus type 31 identified in Northeastern Brazil

Chagas, Bárbara Simas; Batista, Marcus Vinícius de Aragão; Guimarães, Vilma; Balbino, Valdir Queiroz; Crovella, Sérgio; Freitas, Antonio Carlos de

doi:10.1016/j.ygyno.2011.07.008

Cited by 21 publications

(26 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…E5, E6 and E7 oncogenes displayed characteristics of the alternative model, Kimura's two parameter model, suggesting that these mutations may be cyclic in frequency in the Sichuan population. In these genes, the non-synonymous mutations C285T, A297G, A475G, C520T, C626T, G695A, A743G, C737G, A3975G, C3981G, G4005A, T4053A and A4059G can lead to changes to polarity, hydropathic potential and the amino acid side chain, which potentially altered the folding of the oncoprotein (34).…”

Section: Variation Of E7 At Nucleotide Position ---------------------mentioning

confidence: 99%

Genetic variability in E5, E6, E7 and L1 genes of human papillomavirus type 31

Zhang

Wang

et al. 2018

Mol Med Report

View full text Add to dashboard Cite

Human papillomavirus (HPV) type 31 is an important pathogenic subtype associated with cervical cancer. The aims of the present study were to analyze E5, E6, E7 and L1 gene mutations of HPV‑31 among females, and to elucidate the evolutionary associations between them. In total, 87 positive samples were collected. The E5, E6, E7 and L1 genes were amplified by polymerase chain reaction and sequenced. Subsequently, two phylogenetic trees were constructed from the nucleotide sequences of the E5, E6 and E7 and the L1 variants of HPV‑31. In total, 31 mutation sites of E5, E6 and E7 genes were identified, of which 16 were non‑synonymous. T4053A (F80I), C285T (H60Y), C520T (A138V) and A743G (K62E) were the most common non‑synonymous mutations. A total of 30 mutation sites of L1 genes were identified, of which four were non‑synonymous. The most common non‑synonymous mutations of L1 genes were A6350G (T29A) and C6372A (T36N). By phylogenetic analysis, A and C variants were most frequently detected, while B variants were less frequently detected in this population. The sequence variation data obtained in the present study provides a foundation for future research regarding HPV‑induced oncogenesis, and may prove valuable for developing diagnostic probes and in the design of HPV vaccines for targeted populations.

show abstract

Section: Variation Of E7 At Nucleotide Position ---------------------mentioning

confidence: 99%

Genetic variability in E5, E6, E7 and L1 genes of human papillomavirus type 31

Zhang

Wang

et al. 2018

Mol Med Report

View full text Add to dashboard Cite

show abstract

“…1 Clinical relevance of HPV31 variants has been rarely described, [13][14][15] although the intratypic variations in the L1, E6, E7 and long control region were recognized. [14][15][16][17][18][19][20][21] A recent study by Chen et al 22 has defined HPV31 variants as A, B and C lineages based on the whole genome analyses. This provides a basis to view the variant as a distinct phylogenetic entity and better understand the variant-related pathogenesis of cervical lesion.…”

mentioning

confidence: 99%

Association of human papillomavirus type 31 variants with risk of cervical intraepithelial neoplasia grades 2–3

Schiffman

Koutsky

et al. 2012

Intl Journal of Cancer

View full text Add to dashboard Cite

Although the lineages of human papillomavirus type 31 (HPV31) variants are recognized, their clinical relevance is unknown. The purpose of our study was to examine risk of cervical intraepithelial neoplasia Grades 2-3 (CIN2/3) by HPV31 variants. Study subjects were women who participated in the atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion Triage Study and who had HPV31 infections detected at one or more visits. They were followed semi-annually over 2 years for detection of HPV DNA and cervical lesion. HPV31 isolates were characterized by DNA sequencing and assigned into 1 of 3 variant lineages. CIN2/3 was histologically confirmed in 127 (27.0%) of the 470 HPV31-positive women, 83 diagnosed at the first HPV31-positive visit and 44 thereafter. The odds ratio for the association of 2-year cumulative risk of CIN2/3 was 1.7 (95% CI: 1.0-2.9) for infections with A variants and 2.2 (95% CI: 1.2-3.9) for infections with B variants as compared to those with C variants. Among women without CIN2/3 at the first HPV31-positive visit, the risk of subsequent CIN2/3 was 2.2-fold greater for those with A variants (95% CI: 1.0-4.8) and 2.0-fold greater for those with B variants (95% CI: 0.9-4.9) as compared to those with C variants. Similar associations were observed when CIN3 was used as the endpoint. The findings from our study help to tag HPV31 variants that differ in risk of CIN2/3 and to explain in part why some HPV31 infections regress spontaneously and others lead to disease progression.Cervical infection with human papillomavirus (HPV) types is a necessary cause of cervical cancer and its precursor, cervical intraepithelial neoplasia Grades 2-3 (CIN2/3). 1-3 To date, >150 papillomavirus types have been fully characterized and classified, from the higher to lower taxon, as genera, species and type. 4,5 HPV types are known to differ in their tropisms and oncogenic potentials. Studies of the intratypic variation, i.e., the variant, a level below the taxon of type, have focused mainly on HPV16 and HPV18, showing that some variants were more aggressive than others. [6][7][8][9][10][11][12] HPV31 is one of the oncogenic types, most closely related to HPV16. Prevalence of some HPV types may vary geographically. Results from a recent meta-analysis (including 215 studies worldwide) have shown that on average prevalence of HPV31 infection ranks fourth, after types 16, 18 and 45, in cases of cervical cancer and second, only after type 16, in women with high-grade squamous intraepithelial lesion (referring both to cytologically detected high-grade lesions and histologically diagnosed CIN2/3 or carcinoma in situ in this analysis). 1 Clinical relevance of HPV31 variants has been rarely described, 13-15 although the intratypic variations in the L1, E6, E7 and long control region were recognized. 14-21 A recent study by Chen et al. 22 has defined HPV31 variants as A, B and C lineages based on the whole genome analyses. This provides a basis to view the variant as a distinct phylogenet...

show abstract

“…Human papillomavirus 31 (HPV31) is one of the oncogenic types most closely related to HPV16 1. Studies of HPV31 DNA intratypic variations have demonstrated the presence of a variety of variants in all populations examined 2–9. As suggested by an analysis of the whole HPV31 genome,10 these variants could be phylogenetically classified into one of three lineages ( i.e ., group A, B and C).…”

mentioning

confidence: 99%

“…1 Studies of HPV31 DNA intratypic variations have demonstrated the presence of a variety of variants in all populations examined. [2][3][4][5][6][7][8][9] As suggested by an analysis of the whole HPV31 genome, 10 these variants could be phylogenetically classified into one of three lineages (i.e., group A, B and C). Results from our recent study indicated that such a genotypic classification reflects the clinical relevance of the variants, as women with A or B, compared with C, variants were at a significantly higher risk of cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3).…”

mentioning

confidence: 99%

Persistence of newly detected human papillomavirus type 31 infection, stratified by variant lineage

Schiffman

Koutsky

et al. 2012

Intl Journal of Cancer

View full text Add to dashboard Cite

Variants of human papillomavirus (HPV) type 31 have been shown to be related both to risk of cervical lesions and racial composition of a population. It is largely undetermined whether variants differ in their likelihood of persistence. Study subjects were women who participated in the ASCUS‐LSIL Triage Study and who had a newly detected HPV31 infection during a two‐year follow‐up with six‐month intervals. HPV31 isolates were characterized by sequencing and assigned to one of three variant lineages. Loss of the newly detected HPV31 infection was detected in 76 (47.5%) of the 160 women (32/67 with A variants, 16/27 with B variants and 28/66 with C variants). The adjusted hazard ratio associating loss of the infection was 1.2 (95% CI, 0.7–2.1) for women with A variants and 2.1 (95% CI, 1.2–3.5) for women with B variants when compared with those with C variants. Infections with A and C variants were detected in 50 and 41 Caucasian women and in 15 and 23 African‐American women, respectively. The likelihood of clearance of the infection was significantly lower in African‐American women with C variants than in African‐American women with A variants (p = 0.05). There was no difference in the likelihood of clearance between A and C variants among Caucasian women. Our data indicated that infections with B variants were more likely to resolve than those with C variants. The difference in clearance of A vs. C variants in African‐Americans, but not in Caucasians, suggests a possibility of the race‐related influence in retaining the variant‐specific infection.

show abstract

New variants of E6 and E7 oncogenes of human papillomavirus type 31 identified in Northeastern Brazil

Cited by 21 publications

References 27 publications

Genetic variability in E5, E6, E7 and L1 genes of human papillomavirus type 31

Genetic variability in E5, E6, E7 and L1 genes of human papillomavirus type 31

Association of human papillomavirus type 31 variants with risk of cervical intraepithelial neoplasia grades 2–3

Persistence of newly detected human papillomavirus type 31 infection, stratified by variant lineage

Contact Info

Product

Resources

About